Based on the understanding of the canonical EGFR activation pathways, ligand induced dimerization of the receptor and activation of the tyrosine kinase activity of the receptor, anti-EGFR therapeutics have been developed for cancer therapy: monoclonal antibodies that block EGFR from binding to its activating ligands and ATP mimicking small molecule inhibitors that compete with ATP for the binding of tyrosine kinase domain of EGFR. Here, EGFR is linked to cancer.